De Cristofaro, Raimondo

De Cristofaro, Raimondo  

ROMA - Dipartimento di Medicina e chirurgia traslazionale  

Mostra records
Risultati 1 - 20 di 125 (tempo di esecuzione: 0.027 secondi).
Data di pubblicazione Titolo Autore(i) File
1-gen-2022 Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus Coppola, A.; Franchini, M.; Pappagallo, G.; Borchiellini, A.; De Cristofaro, R.; Molinari, A. C.; Santoro, R. C.; Santoro, C.; Tagliaferri, A.
1-gen-2022 Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience Cesari, Francesca; Sorrentino, Silvia; Maria Gori, Anna; Rogolino, Angela; De Cristofaro, Raimondo; Giusti, Betti; Sticchi, Elena; De Candia, Erica; Marcucci, Rossella
1-gen-2022 Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation D'Amario, Domenico; Galli, Mattia; Cappannoli, Luigi; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; E Riccioni, Maria; Vergallo, Rocco; A Montone, Rocco; Conte, Amelia; Meleo, Emiliana; Lancellotti, Stefano; Sacco, Monica; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2021 Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 1, Domenico D'Amario; Galli, Mattia; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; Cappannoli, Luigi; Riccioni, Maria Elena; Giuseppina Annetta, Maria; Di Stefano, Gaetano; Piccinni, Carlo; Vergallo, Rocco; Antonio Montone, Rocco; Maria Leone, Antonio; Niccoli, Giampaolo; Sabatelli, Mario; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2021 Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis Lazzareschi, I.; Curatola, A.; Gatto, A.; Maellaro, F.; Frassanito, P.; Basso, M.; De Cristofaro, R.; Valentini, P.
1-gen-2021 Direct oral anticoagulants and therapeutic adherence: do not let your guard down Di Gennaro, L.; Monaco, M.; Riccio, C.; De Candia, E.; Alberelli, M. A.; di Martino, C.; Basso, M.; Ferretti, M. A.; Lancellotti, S.; De Cristofaro, R.
1-gen-2021 Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory? Di Gennaro, L.; Marazzi, F.; De Cristofaro, R.
1-gen-2021 Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? Cappannoli, Luigi; Galli, Mattia; De Cristofaro, Raimondo; Crea, Filippo; D'Amario, Domenico
1-gen-2021 Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? Cappannoli, L.; Galli, M.; De Cristofaro, R.; Crea, F.; D'Amario, D.
1-gen-2021 Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? Covino, M.; De Matteis, G.; Della Polla, D.; Burzo, M. L.; Pascale, M. M.; Santoro, M.; De Cristofaro, R.; Gasbarrini, A.; De Candia, E.; Franceschi, F.
1-gen-2021 From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 Vinci, R.; Pedicino, D.; Andreotti, F.; Russo, G.; D'Aiello, A.; De Cristofaro, R.; Crea, F.; Liuzzo, G.
1-gen-2021 ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study D'Amario, D.; Galli, M.; Canonico, F.; Restivo, A.; Arcudi, A.; Scacciavillani, R.; Cappannoli, L.; Riccioni, M. E.; Annetta, M. G.; Di Stefano, G.; Piccinni, C.; Vergallo, R.; Montone, R. A.; Leone, A. M.; Niccoli, G.; Sabatelli, M.; Antonelli, M.; Andreotti, F.; De Cristofaro, R.; Crea, F.
1-gen-2021 Sirtuin 5, vascular endothelium and fibrinolysis: a deadly embrace? Rocca, Bianca; De Cristofaro, Raimondo
1-gen-2021 Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis? De Cristofaro, R.; Sanguinetti, M.
1-gen-2020 Hemophilia A and von Willebrand deficiency: therapeutic implications Basso, Maria; Lazzareschi, Ilaria; Curatola, Antonietta; Di Gennaro, Leonardo; Buonsenso, Danilo; Gatto, Antonio; De Candia, Erica; De Cristofaro, Raimondo
1-gen-2020 Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia Sacco, Monica; Ranalli, Paola; Lancellotti, Stefano; Petrucci, Giovanna; Dragani, Alfredo; Rocca, Bianca; De Cristofaro, Raimondo
1-gen-2020 Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains Sacco, M.; Lancellotti, S.; Ferrarese, M.; Bernardi, F.; Pinotti, M.; Tardugno, M.; de Candia, E.; Di Gennaro, L.; Basso, M.; Giusti, B.; Papi, M.; Perini, G.; Castaman, G.; de Cristofaro, R.
1-gen-2020 ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 1, Domenico D'Amario; Galli, Mattia; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; Cappannoli, Luigi; Riccioni, Maria Elena; Annetta, Maria Giuseppina; Di Stefano, Gaetano; Piccinni, Carlo; Vergallo, Rocco; Montone, Rocco Antonio; Leone, Antonio Maria; Niccoli, Giampaolo; Sabatelli, Mario; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2019 A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease Peyvandi, Flora; Castaman, Giancarlo; Gresele, Paolo; De Cristofaro, Raimondo; Schinco, Piercarla; Bertomoro, Antonella; Morfini, Massino; Gamba, Gabriella; Barillari, Giovanni; Jiménez-Yuste, Víctor; Königs, Cristoph; Iorio, Alfonso; Federici, Augusto B
1-gen-2019 Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy Di Gennaro, L.; Lancellotti, S.; De Cristofaro, R.; De Candia, E.